Table 4.

Glucose metabolism by group

Characteristic	HS (n=82)	Het (n=81)	GS (n=77)	ANOVA P Value
Antidiabetic drugs	0	6	4
Insulin	0	2	0
Metformin/sulfamides	0/0	5/2	2/0
DPP4 inhibitors	0	2	1
Hypolipemiant treatment
Statins/fibrates	0/0	10/9	8/6
Plasma
Glucose T0, mM	4.8 [4.7; 5.2]	5.0 [4.6; 5.4]	5.1 [4.8; 5.5]	0.01
Glucose T120, mM	5.3 [4.6; 5.9]a	5.4 [4.7; 6.1]a	6.2 [5.5; 7.1]	<0.001
Change in glucose (T120–T0)	0.50 [-0.10; 1.20]b	0.40 [-0.30; 1.20]b	1.10 [0.30; 1.80]	<0.001
Insulin T0, mUI/l	4.4 [3.1; 5.4]a	4.4 [3.2; 7.3]b	6.8 [4.3; 10.8]	<0.001
Insulin T120, mUI/l	15.9 [8.6; 26.2]a	22.0 [10.4; 35.9]b	28.6 [17.8; 47.7]	<0.001
Change in insulin (T120–T0)	11.1 [5.8; 21.7]a	18.0 [7.4; 32.1]	21.3 [11.7; 41.0]	<0.001
QUICKI T0	0.38 [0.37; 0.40]a	0.38 [0.35; 0.41]b	0.35 [0.33; 0.39]	<0.001
IR index T0	0.50 [0.38; 0.60]a	0.51 [0.39; 0.80]a	0.77 [0.48; 1.22]	<0.001
Cholesterol, mM	5.09 [4.27; 5.63]	4.98 [4.37; 5.67]	5.27 [4.63; 6.01]	0.1
HDL cholesterol, mM	1.36 [1.18; 1.58]	1.48 [1.23; 1.70]	1.45 [1.13; 1.66]	0.10
LDL cholesterol, mM	3.07 [2.56; 3.67]	3.01 [2.44; 3.72]	3.34 [2.80; 3.92]	0.23
Triglycerides, mM	1.00 [0.71; 1.43]	1.00 [0.72; 1.33]	1.10 [0.83; 1.60]	0.11
ALAT, UI/L	17 [14; 24]a	18 [13; 23]a	23 [17; 39]	<0.001
ASAT, UI/L	16 [12; 19]a	17 [13; 22]a	21 [17; 30]	<0.001
GGT, UI/L	24 [14; 33]	20 [14; 28]	24 [16; 43]	0.27
ALP, UI/L	55 [44; 64]	56 [47; 63]	51 [42; 61]	0.10

Data are presented as median [IQR]. ANOVA was performed to compare Het or HS versus patients with GS. If significant, Tukey or Dunn test was performed to compare HS and Het and HS or Het versus GS (^a,b,c). T0, before glucose load; T120, after glucose load; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; GGT, gamma-glutamyl transferase; ALP, alkalin phosphaphatase.

^aP<0.001.

^bP<0.05.